PersonFounderExecutive
Rachel Humphrey
Rachel W. Humphrey, MD, is the founding CEO of Normunity, a Boston and New Haven biotech building a new class of cancer drugs called immune normalizers, drugs designed to free the immune system to attack tumors it normally ignores. Before Normunity she helped bring three blockbuster cancer therapies to patients: Yervoy at Bristol Myers Squibb, Imfinzi at AstraZeneca, and Nexavar at Bayer. She partnered with Yale immunology pioneer Lieping Chen to translate his discoveries at the cancer-immune interface into medicines, raising $65M to launch in 2022 and a $75M Series B in January 2025 to push lead program NRM-823 into the clinic.
rachel humphreynormunityimmuno-oncologycancer immunotherapybiotech ceoimmune normalizers